

Myocardial strain imaging

Clinical Policy ID: CCP.1207

Recent review date: 6/2025

Next review date: 10/2026

Policy contains: Deformation imaging; echocardiographic strain imaging; hypertrophic cardiomyopathy; myocardial strain; and speckle tracking.

AmeriHealth Caritas Next has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Next's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by AmeriHealth Caritas Next when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Next's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Next's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Next will update its clinical policies as necessary. AmeriHealth Caritas Next's clinical policies are not guarantees of payment.

Coverage policy

Echocardiographic assessment of myocardial strain to measure cardiac impairment is investigational/not clinically proven and, therefore, not medically necessary.

Limitations

No limitations were identified for this policy.

Alternative covered services

- Cardiac magnetic resonance.
- Chest radiography.
- Computed tomography.
- Electrocardiography.
- Myocardial perfusion imaging.
- Radionuclide ventriculography.
- Stress echocardiography.
- Transthoracic or transesophageal echocardiography, including tissue Doppler imaging.

Background

Myocardial strain imaging evaluates the function of the heart muscle using cardiac ultrasound. In myocardial imaging, the terms “strain” and “strain rate” define myocardial wall deformation that occurs by the application of a force (Collier, 2017). Strain is a unitless measurement used to describe dimensional or deformational change resulting from local shortening, thickening, and lengthening of the myocardium during the cardiac cycle. The dimensions of strain are longitudinal, radial, circumferential, and rotational (ventricular twist). Strain rate quantifies the speed of myocardial deformation.

The amount of deformation (positive or negative strain) is defined as the percent change in the length of myocardial segment from a relaxed to contractile state (Collier, 2017). Positive strain values describe thickening, and negative values describe shortening, of a given myocardial segment related to its original length. Both strain and strain rate assess systolic function (especially regional contractile function) but are not measures of contractility, because deformation is load dependent (Voigt, 2019).

Myocardial deformation data may be derived noninvasively using echocardiography or cardiac magnetic resonance (Voigt, 2019). Transthoracic echocardiography is an established modality for ventricular wall motion analysis and assessment of regional myocardial function. Through tissue Doppler imaging, calculation of myocardial strain rate deformation became possible from apical windows with left ventricular shortening and lengthening with Doppler scan lines. However, tissue Doppler imaging provides a one-dimensional view and permits limited evaluation of deformation. It is highly operator dependent, and estimation of wall motion is visual and subjective with high interobserver and intra-observer variability.

Speckle tracking echocardiography is a recent development based on two-dimensional digital gray-scale imaging on echocardiography, which is composed of several bright acoustic markers called “speckles” produced by the scatter of the ultrasound beam by the tissue (Voigt, 2019). Three-dimensional speckle tracking is now available. The motion pattern of the speckles reflects the motion pattern of myocardial tissue at the endocardial border from which strain and strain rate can be calculated. It allows the myocardium, particularly the left ventricle, to be viewed at various angles during the echocardiographic procedure and provides unique quantifiable information on regional and global myocardial function.

Speckle tracking echocardiography software is applied during post-processing to analyze regions of interest frame-by-frame, but the methods and algorithms are strongly vendor specific, leading to inter-vendor variability. The European Association of Cardiovascular Imaging and the American Society of Echocardiography initiated a consensus task force to standardize definitions and nomenclature in both atrial and ventricular strain imaging with two-dimensional speckle tracking technology (Badano, 2018; Voigt, 2015). The goal of this effort was to reduce inter-vendor differences and ambiguities in the strain algorithms.

The most studied parameter using speckle tracking data is global longitudinal strain, as it represents a shortening of the endocardial fibers that are usually the first affected in most cardiomyopathies (Voigt, 2019). Left ventricular ejection fraction is an established, but relatively late, load-dependent marker of systolic function, resulting in low sensitivity for detecting subclinical changes in ejection fraction. Myocardial strain analysis can discriminate between active and passive movement of myocardial segments and can permit separate assessment of the dimensional components of myocardial deformation that are not visually assessable on transthoracic echocardiography. As such, it has potentially wide clinical application for the diagnosis, prognosis, and provision of treatment of myocardial disease, in particular, chemotherapy-related cardiac dysfunction.

The high prevalence of cancer and the growing number of chemotherapy drugs with the potential for cardiotoxicity used to treat cancer patients make precise measurements of various organ functions a vital part of treatment. Patients with heart failure after chemotherapy are treated according to standard heart failure protocols. The most commonly measured cardiac functions in post-chemotherapy patients are left ventricular

systolic function and left ventricular ejection fraction (Smiseth, 2016). Chemotherapy-related cardiac dysfunction was originally measured by periodic surveillance of left ventricular ejection fraction through nuclear imaging, magnetic resonance imaging, and other means. Echocardiography now has surpassed these modalities as the preferred method of measuring cardiac dysfunction, as it is more accurate, available, and portable, and less radioactive (Abdel-Qadir, 2016).

Findings

Guidelines

Some professional societies have produced guidelines on types of echocardiography, including assessment of myocardial strain for chemotherapy drugs with Type 1 or 2 cardiotoxicity.

To assess cardiac involvement in patients with primary systemic light chain amyloidosis, the National Comprehensive Cancer Network (2025) recommended transthoracic echocardiogram with global longitudinal strain imaging when cardiovascular magnetic resonance is not feasible or optimal in certain circumstances, but the guideline cited no supportive evidence for this use.

According to the American Society of Echocardiography, global longitudinal strain using speckle-tracking echocardiography may be added to tissue Doppler imaging to monitor myocardial function in pediatric patients undergoing cancer treatment, although the Society acknowledges a lack of evidence supporting the prognostic significance of early changes in left ventricular function determined by global longitudinal strain. The Society recommends more data before incorporating strain measurement routinely in therapeutic decisions to monitor cardiotoxicity in cancer treatment (Mertens, 2023).

In 2019, the American College of Cardiology, leading a group of ten professional medical organizations, issued appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease, including indications for strain and strain rate imaging (Doherty, 2019). Their consensus panel rated numerous indications as “appropriate,” “may be appropriate,” or “rarely appropriate” based on an assessment of benefits, risks, and judgment that the procedure is generally acceptable and reasonable for the indication.

For strain or strain rate imaging, only four indications were rated as “appropriate” and represent clinical scenarios where the expected incremental information from speckle or tissue Doppler, combined with clinical judgment, may exceed the expected negative consequences. All other 77 indications were rated as “may be appropriate” (n = 14) or “rarely appropriate” (n = 63), reflecting the uncertainty in the clinical value of myocardial strain data using two-dimensional speckle tracking for these scenarios. The four indications rated as “appropriate” are (Doherty, 2019):

- Initial evaluation prior to exposure to medications/radiation that could result in cardiotoxicity/heart failure.
- Re-evaluation (one year) in a patient previously or currently undergoing therapy with potentially cardiotoxic agents.
- Periodic re-evaluation in a patient undergoing therapy with cardiotoxic agents with worsening symptoms.
- Evaluation of suspected hypertrophic cardiomyopathy to clarify initial diagnostic testing (commonly when transthoracic echocardiography is nondiagnostic).

Another American College of Cardiology guideline (Ommen, 2024) stated that while changes in left ventricular systolic strain and diastolic function can precede definitive hypertrophy on echocardiography, the clinical significance of subclinical structural and functional abnormalities, such as myocardial strain, is unclear and treatment decisions are usually not based on these findings alone.

The American Society for Clinical Oncology guideline for prevention and monitoring of cardiac dysfunction of adult cancers endorsed routine echocardiography in metastatic breast cancer. It also recommended echocardiography in post-chemotherapy patients with signs and symptoms of cardiac disease, six to 12 months after chemotherapy in high-risk patients. If echocardiography is unavailable or not technically feasible, cardiac magnetic resonance imaging or multi-gated acquisition scans can be used. Reports in the professional medical literature address these indications for myocardial strain imaging. However, none address whether the procedure affects eventual patient outcomes (Armenian, 2017).

Evidence review

Results of early systematic reviews and large studies suggested a potential complementary role for myocardial strain imaging to detect subclinical early left ventricular dysfunction in patients undergoing chemotherapy, most notably anthracycline therapy, who may benefit from early initiation of cardioprotective treatment (Armstrong, 2015; Tuzovic, 2018). The body of literature is expanding to other clinical conditions with associated heart dysfunction to assess whether myocardial strain imaging of atria or ventricles has prognostic or diagnostic significance.

Several systematic reviews published since Doherty (2019) identified significant limitations in the literature that prevented meaningful evaluation of clinical efficacy through meta-analysis in most instances. The main limitations are the inclusion of only retrospective or prospective cohort studies and the large degree of heterogeneity among studies, particularly the variation in strain values among methods, modalities, and software versions that prevented determination of a clearly defined threshold value for left ventricular global longitudinal strain, which would trigger clinical action and any subsequent impact on clinical care. Current evidence is insufficient to support that using myocardial strain imaging in combination with other modalities and standard imaging affects clinical management or improves patient outcomes.

A systematic review and meta-analysis of 16 studies of breast cancer patients given anthracyclines or trastuzumab showed significant reductions in two-dimensional left ventricular ejection fraction and speckle tracking echocardiography parameters early in chemotherapy. Peak systolic global longitudinal strain was the most consistently detected early myocardial change, upholding the role of monitoring and starting cardioprotective treatment (Bergamini, 2019).

A systematic review/meta-analysis of 21 studies ($n = 1,782$) of cancer therapy-related cardiac dysfunction diagnosed by echocardiographic left ventricular global longitudinal strain included patients with breast cancer, hematologic malignancies, or sarcomas treated with anthracyclines with or without trastuzumab. The rate of positive tests ranged from 9.3% to 43.8% after a mean follow-up of 4.2 to 23.0 months. Worse global longitudinal strain was associated with a higher risk of cardiac dysfunction. Authors characterized the results as “good prognostic performance” of strain for cardiac dysfunction (Oikonomou, 2019).

In a systematic review/meta-analysis of 42 studies ($n = 5,403$) of children with cancer undergoing chemotherapy, while myocardial strain imaging by speckle-tracking echocardiography documented early evidence of myocardial injury, additional evidence on risk parameters was needed to support its adoption for clinical use, and more data were required for the better understanding of myocardial deformation parameters in risk stratification (Li, 2022). Another systematic review of eight studies ($n = 979$) showed left ventricular global longitudinal strain was significantly lower in all hypertensive groups compared with controls without hypertension (Tadic, 2021).

A systematic review/meta-analysis of three studies ($n = 1,332$) found myocardial strain by strain-encoded magnetic resonance imaging accurately predicted all-cause mortality and other endpoints ($P < .001$). However, subjects had heart failure or coronary artery disease, with no mention of prior cancer or chemotherapy (Korosoglou, 2024).

In a systematic review and meta-analysis of 13 studies (553 with amyloidosis and 575 healthy controls), amyloidosis had a large negative effect on left ventricular global longitudinal strain, primarily related to the deterioration of segmental longitudinal strain at the basal level and mid-level, but spared apical involvement. The effect of myocardial strain information on patient management or outcomes requires further study (Sonaglioni, 2025).

In 2021, we updated the references and added studies of other potential indications for myocardial strain imaging, which required no policy changes. The following indications are unrelated to provision of cardiotoxic agents, primarily for early detection and outcome prediction, the results of which would not alter American College of Cardiology (Doherty, 2019) findings:

- To evaluate hypertrophic cardiomyopathy. Two systematic reviews (Dorobantu, 2021, 14 studies, n = 809 total patients; Tower-Rader, 2019, 14 studies, n = 3,154 total patients) confirm an association between abnormal left ventricular global longitudinal strain and adverse composite cardiac outcomes and ventricular arrhythmias, and the ability of left ventricular global longitudinal strain data derived from speckle tracking echocardiography to detect left ventricular dysfunction, especially in the setting of a normal left ventricular ejection fraction.
- After repair of Tetralogy of Fallot using speckle tracking echocardiography, tissue Doppler imaging, or cardiac magnetic resonance feature tracking (Cheung, 2019, 10 studies).
- To predict response to catheter ablation (Bajraktari, 2020, 13 studies, n = 1,179 total patients; Nielsen, 2020, 12 studies, n = 1,025 total patients).
- To predict response to cardiac resynchronization therapy using ventricular strain (Bazoukis, 2022; n = 12 studies with 1,004 total patients).
- For early detection of subclinical ventricular dysfunction associated with:
 - Systemic lupus erythematosus (Di Minno, 2020, nine studies).
 - Sickle cell disease (Whipple, 2021, 17 studies, n = 887 total patients of all genotypes).
 - Hypertensive pregnancy disorders (Moors, 2020, 16 studies, n = 870 index cases and 693 normotensive controls).
 - Acute cellular rejection in heart transplant recipients (Elkaryoni, 2020, 10 studies, n = 511 total patients; Zhu, 2020, seven studies).
- For prognosis using ventricular longitudinal strain:
 - In patients with coronavirus disease 2019 (Wibowo, 2021, seven studies, n = 612 total patients).
 - In patients with sepsis (Vallabhajosyula, 2019, five studies, n = 561 patients).
 - In patients with subclinical primary mitral regurgitation, to guide timing of mitral valve surgery (Modaragamage Dona, 2021, 12 studies).
 - In fetuses during gestation (van Oostrum, 2020a, 23 studies; van Oostrum, 2020b, four studies).

In 2022, we updated the references which warranted no policy changes.

In 2024, we reactivated and updated the policy, and changed coverage from medically necessary to investigational, based on guideline recommendations (Mertens, 2023) stating a lack of evidence that myocardial strain imaging affects outcomes.

In 2025, we updated the references and added a new guideline and research on the influence of amyloidosis on myocardial strain measurement and the potential use of myocardial strain imaging in this population. No policy changes are warranted.

References

On March 20, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “echocardiographic strain imaging,” “deformation imaging,” “myocardial strain,” and “speckle tracking.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Abdel-Qadir H, Amir E, Thavendiranathan P. Prevention, detection, and management of chemotherapy-related cardiac dysfunction. *Can J Cardiol*. 2016;32(7):891-899. Doi: 10.1016/j.cjca.2016.01.028.

Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2017;35(8):893-911. Doi: 10.1200/jco.2016.70.5400.

Armstrong GT, Joshi VM, Ness KK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: Results from the St. Jude Lifetime Cohort Study. *J Am Coll Cardiol*. 2015;65(23):2511-2522. Doi: 10.1016/j.jacc.2015.04.013.

Badano LP, Koliass TJ, Muraru D, et al. Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: A consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. *Eur Heart J Cardiovasc Imaging*. 2018;19(6):591-600. Doi: 10.1093/ehjci/jej042.

Bajraktari G, Bytyçi I, Henein MY. Left atrial structure and function predictors of recurrent fibrillation after catheter ablation: A systematic review and meta-analysis. *Clin Physiol Funct Imaging*. 2020;40(1):1-13. Doi: 10.1111/cpf.12595.

Bazoukis G, Thomopoulos C, Tse G, Tsioufis K, Nihoyannopoulos P. Global longitudinal strain predicts responders after cardiac resynchronization therapy-a systematic review and meta-analysis. *Heart Fail Rev*. 2022;27(3):827-836. Doi: 10.1007/s10741-021-10094-w.

Bergamini C, Dolci G, Truong S, et al. Role of speckle tracking echocardiography in the evaluation of breast cancer patients undergoing chemotherapy: Review and meta-analysis of the literature. *Cardiovasc Toxicol*. 2019;19(6):485-492. Doi: 10.1007/s12012-019-09523-y.

Cheung YF, Yu CKM, So EKF, Li VWY, Wong WHS. Atrial strain imaging after repair of Tetralogy of Fallot: A systematic review. *Ultrasound Med Biol*. 2019;45(8):1896-1908. Doi: 10.1016/j.ultrasmedbio.2019.04.032.

Collier P, Phelan D, Klein A. A test in context: Myocardial strain measured by speckle-tracking echocardiography. *J Am Coll Cardiol*. 2017;69(8):1043-1056. Doi: 10.1016/j.jacc.2016.12.012.

Di Minno MND, Forte F, Tufano A, et al. Speckle tracking echocardiography in patients with systemic lupus erythematosus: A meta-analysis. *Eur J Intern Med*. 2020;73:16-22. Doi: 10.1016/j.ejim.2019.12.033.

Doherty JJ, Kort SS, Mehran RR. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS. 2019 appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in non-valvular heart disease. *J Am Coll Cardiol*. 2019;73(4):488-516. Doi: 10.1016/j.jacc.2018.10.038.

Dorobantu DM, Wadey CA, Amir NH, et al. The role of speckle tracking echocardiography in the evaluation of common inherited cardiomyopathies in children and adolescents: A systematic review. *Diagnostics (Basel)*. 2021;11(4):635. Doi: 10.3390/diagnostics11040635.

Elkaryoni A, Altibi AM, Khan MS, et al. Global longitudinal strain assessment of the left ventricle by speckle tracking echocardiography detects acute cellular rejection in orthotopic heart transplant recipients: A systematic review and meta-analysis. *Echocardiography*. 2020;37(2):302-309. Doi: 10.1111/echo.14586.

Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. *JACC Cardiovasc Imaging*. 2018;11(8):1084-1093. Doi: 10.1016/j.jcmg.2018.06.005.

Korosoglou G, Sagris M, Andre F, et al. Systematic review and meta-analysis for the value of cardiac magnetic resonance strain to predict cardiac outcomes. *Sci Rep*. 2024;14(1):1094. Doi: 10.1038/s41598-023-50835-5.

Li V W-Y, So E K-F, Wong W H-S, Cheung Y-F. Myocardial deformation imaging by speckle-tracking echocardiography for assessment of cardiotoxicity in children during and after chemotherapy: A systematic review and meta-analysis. *J Am Soc Echocardiogr*. 2022;35(6):629-656. Doi: 10.1016/j.echo.2022.01.017.

Modaragamage Dona AC, Afoke J, Punjabi PP, Kanaganayagam GS. Global longitudinal strain to determine optimal timing for surgery in primary mitral regurgitation: A systematic review. *J Card Surg*. 2021;36(7):2458-2466. Doi: 10.1111/jocs.15521.

Moors S, van Oostrum NHM, Rabotti C, et al. Speckle tracking echocardiography in hypertensive pregnancy disorders: A systematic review. *Obstet Gynecol Surv*. 2020;75(8):497-509. Doi: 10.1097/ogx.0000000000000811.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Systemic light chain amyloidosis. Version 2.2025. www.nccn.org. Published March 12, 2025.

Nielsen AB, Skaarup KG, Lassen MCH, et al. Usefulness of left atrial speckle tracking echocardiography in predicting recurrence of atrial fibrillation after radiofrequency ablation: A systematic review and meta-analysis. *Int J Cardiovasc Imaging*. 2020;36(7):1293-1309. Doi: 10.1007/s10554-020-01828-2.

O'Brien P, Matheson K, Jevakumar A, Anderson K, Younis T. The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: A systematic review and meta-analysis. *Breast Cancer Res Treat*. 2019;174(2):357-363. Doi: 10.1007/s10549-018-05114-7.

Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: A systematic review and meta-analysis. *JAMA Cardiol*. 2019;4(10):1007-1018. Doi: 10.1001/jamacardio.2019.2952.

Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: A report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. *J Am Coll Cardiol*. 2024;83(23):2324-2405. Doi: 10.1016/j.jacc.2024.02.014.

Smiseth OA, Torp H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging: How useful is it in clinical decision making? *Eur Heart J*. 2016;37(15):1196-1207. Doi: 10.1093/eurheartj/ehv529.

Sonaglioni A, Torretta P, Nicolosi GL, Lombardo M. Left ventricular mechanics assessment in amyloidosis patients: A systematic review and meta-analysis. *Minerva Cardiol Angiol*. 2025. Doi: 10.23736/s2724-5683.24.06683-3.

Tadic M, Sala C, Carugo S, Mancina G, Grassi G, Cuspidi C. Myocardial strain and left ventricular geometry: A meta-analysis of echocardiographic studies in systemic hypertension. *J Hypertens*. 2021;39(11):2297-2306. Doi: 10.1097/HJH0000000000002911.

Tower-Rader A, Mohananey D, To A, et al. Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: A systematic review of existing literature. *JACC Cardiovasc Imaging*. 2019;12(10):1930-1942. Doi: 10.1016/j.jcmg.2018.07.016.

Tuzovic M, Wu PT, Kianmahd S, Nguyen KL. Natural history of myocardial deformation in children, adolescents, and young adults exposed to anthracyclines: Systematic review and meta-analysis. *Echocardiography*. 2018;35(7):922-934. Doi: 10.1111/echo.13871.

Vallabhajosyula S, Rayes HA, Sakhuja A, et al. Global longitudinal strain using speckle-tracking echocardiography as a mortality predictor in sepsis: A systematic review. *J Intensive Care Med*. 2019;34(2):87-93. Doi: 10.1177/0885066618761750.

van Oostrum NHM, de Vet CM, van der Woude DAA, et al. Fetal strain and strain rate during pregnancy measured with speckle tracking echocardiography: A systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2020;250:178-187. Doi: 10.1016/j.ejogrb.2020.04.002. (a)

van Oostrum NHM, Derks K, van der Woude DAA, et al. Two-dimensional speckle tracking echocardiography in fetal growth restriction: A systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2020;254:87-94. Doi: 10.1016/j.ejogrb.2020.08.052. (b)

Voigt JU, Cvijic M. 2- and 3-dimensional myocardial strain in cardiac health and disease. *JACC Cardiovasc Imaging*. 2019;12(9):1849-1863. Doi: 10.1016/j.jcmg.2019.01.044.

Whipple NS, Joshi VM, Naik RJ, et al. Sick cell disease and ventricular myocardial strain: A systematic review. *Pediatr Blood Cancer*. 2021;68(6):e28973. Doi: 10.1002/pbc.28973.

Wibowo A, Pranata R, Astuti A, et al. Left and right ventricular longitudinal strains are associated with poor outcome in COVID-19: A systematic review and meta-analysis. *J Intensive Care*. 2021;9(1):9. Doi: 10.1186/s40560-020-00519-3.

Zhu S, Li M, Tian F, et al. Diagnostic value of myocardial strain using two-dimensional speckle-tracking echocardiography in acute cardiac allograft rejection: A systematic review and meta-analysis. *Echocardiography*. 2020;37(4):561-569. Doi: 10.1111/echo.14637.

Policy updates

11/2015: initial review date and clinical policy effective date: 3/2016

11/2016: Policy references updated.

11/2017: Policy references updated.

11/2018: Policy references updated. Policy ID changed to CCP.1207.

1/2020: Policy references updated.

8/2021: Policy references updated. Coverage limitation clarified.

8/2022: Policy references updated.

6/2024: Policy re-activated and updated. Coverage modified from medically necessary to investigational.

6/2025: Policy references updated.